AWH Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 geg. 2024 @ 23:00):

Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States...

Stats
Dzisiejszy wolumen	48 795.00
Średni wolumen	23 582.00
Kapitalizacja rynkowa	33.12M
EPS	$0 ( 2024-05-15 )
Następna data zysków	( $-0.320 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.470
ATR14	$0.0270 (1.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-13	Hombeck Torsten	Buy	22 000	EMPLOYEE STOCK OPTION (RIGHT TO BUY)
2024-05-13	Sandford Nicole	Buy	80 000	EMPLOYEE STOCK OPTION (RIGHT TO BUY)
2024-05-03	Milligan Sandra	Buy	30 000	EMPLOYEE STOCK OPTION (RIGHT TO BUY)
2024-04-01	Milligan Sandra	Buy	0
2024-02-15	Sandford Nicole	Buy	30 000	Employee stock option (right to buy)

INSIDER POWER
97.86
Last 89 transactions
Buy: 4 380 901 \| Sell: 195 424

Aspira Women's Health Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aspira Women's Health Korelacja - Waluta/Towar

0.51
( weak )

0.00
( neutral )

0.61
( weak )

0.36
( neutral )

0.65
( moderate )

Aspira Women's Health Finanse

Annual	2023
Przychody:	$9.15M
Zysk brutto:	$5.26M (57.48 %)
EPS:	$-1.810

FY	2023
Przychody:	$9.15M
Zysk brutto:	$5.26M (57.48 %)
EPS:	$-1.810

FY	2022
Przychody:	$8.18M
Zysk brutto:	$4.32M (52.77 %)
EPS:	$-41.66

FY	2021
Przychody:	$6.81M
Zysk brutto:	$3.06M (44.95 %)
EPS:	$-0.280

Financial Reports:

No articles found.

Aspira Women's Health Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Aspira Women's Health

Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.